Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned with the supplied label excerpts: the indication and blurred vision adverse reaction are supported, and evaporation-reduction statements are largely consistent. Several other claims (pricing, ocular irritation as most common, lipid-layer stabilization, ocular surface hydration, and manufacturer) are not supported by the provided label text, and key safety-critical label elements were not evaluable from the excerpts.
Category Scores
Accurate Statements
Miebo is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Supported by INDICATIONS AND USAGE (Section 1): indicated for treatment of the signs and symptoms of dry eye disease (DED).
The most common adverse reactions reported in clinical trials of Miebo include blurred vision.
Supported by ADVERSE REACTIONS, Clinical Trials Experience (Section 6.1): 'The most common ocular adverse reaction was blurred vision.'
Miebo is designed to prevent rapid evaporation of tears.
Consistent with Mechanism of Action (Section 12.1): perfluorohexyloctane 'can be expected to reduce evaporation.' (The claim is slightly more specific than the excerpt.)
Miebo reduces tear evaporation.
Supported by Mechanism of Action (Section 12.1): 'can be expected to reduce evaporation.'
Unsupported Statements
The cost of Miebo without insurance can vary significantly based on pharmacy, location, and the specific dosage or quantity prescribed.
No pricing/cost information is provided in the available label sections.
One month's supply of Miebo can cost between $500 and $650 without insurance.
No pricing/cost information is provided in the available label sections.
The most common adverse reactions reported in clinical trials of Miebo include eye irritation.
The provided Section 6.1 excerpt identifies blurred vision as the most common ocular adverse reaction and does not list 'eye irritation' as most common.
Miebo is formulated as a perfluorohexyl octane.
The excerpt supports perfluorohexyloctane (100% perfluorohexyloctane). The claim uses different wording ('perfluorohexyl octane'), which is not directly supported as written.
Miebo is designed to stabilize the lipid layer of the tear film.
No lipid-layer stabilization language appears in the provided Mechanism of Action (Section 12.1) excerpt.
By reducing tear evaporation, Miebo helps improve ocular surface hydration.
No ocular surface hydration benefit is stated in the provided Mechanism of Action (Section 12.1) excerpt.
By reducing tear evaporation, Miebo helps alleviate the symptoms associated with dry eye disease.
While Section 1 supports treatment of signs and symptoms of DED and Section 12.1 discusses reduced evaporation, the provided label excerpt does not explicitly causally connect reduced evaporation to symptom alleviation; it also states the exact mechanism is not known.
Miebo is manufactured by Bausch + Lomb.
No manufacturer information is provided in the available label sections.
Contradictions
Important Omissions
Major safety-critical prescribing information elements (e.g., contraindications, boxed warnings, dosing/administration specifics, and key use-in-specific-populations safety details) were not evaluated because they were not present in the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported or go beyond the provided excerpt (e.g., ocular irritation as most common; lipid-layer stabilization; ocular surface hydration; causal symptom-alleviation linkage). Additionally, the audit does not verify key safety-critical labeling components from the supplied excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are not supported by the supplied FDA label excerpts (pricing, manufacturer, and several mechanism/benefit and adverse-reaction details).
Suggested Improvement
Restrict claims to what is explicitly supported in the provided label sections (Sections 1, 6.1, 11, 12.1) and remove or rephrase unsupported mechanistic benefit, adverse-reaction prominence, and non-label items such as pricing/manufacturer.